Lynparza filed sBLA at FDA for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer. AstraZeneca + Merck Inc.

AstraZeneca and MSD Inc., announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted Priority Review in the US for the maintenance treatment of patients with advanced ovarian cancer who are in complete or partial response to 1st-line platinum-based chemotherapy with bevacizumab. A Prescription Drug User Fee Act (PDUFA) date is set for the second quarter of 2020. The Priority Review by the FDA was based on results from the pivotal Phase III PAOLA-1 trial, which were published in The New England Journal of Medicine. The trial compared Lynparza when added to standard-of-care (SoC) bevacizumab vs. bevacizumab alone in patients with advanced ovarian cancer in the 1st-line maintenance setting, regardless of their biomarker status or outcome from previous surgery. The investigator-assessed results showed Lynparza added to bevacizumab reduced the risk of disease progression or death by 41% based on a hazard ratio of 0.59 (p<0.0001) and improved progression-free survival (pfs) to a median of 22.1 months vs. 16.6 months for patients treated with bevacizumab alone. at two years after trial initiation, 46% of patients treated with lynparza added to bevacizumab showed no disease progression vs. 28% of patients treated with bevacizumab alone. the safety and tolerability profiles of lynparza and bevacizumab were consistent with previous trials for each medicine and showed no detriment to quality of life. see- " olaparib plus bevacizumab as first-line maintenance in ovarian cancer"- isabelle ray-coquard, m.d., ph.d., patricia pautier, m.d., sandro pignata, m.d., ph.d., david pérol, m.d., antonio gonzález-martín, m.d., ph.d et al.,for the paola-1 investigators -december 19, 2019. n engl j med 2019; 381:2416-2428 doi: 10.1056 nejmoa1911361.>